Rakshit Drugs Revenue and Competitors
Estimated Revenue & Valuation
- Rakshit Drugs's estimated annual revenue is currently $10.6M per year.
- Rakshit Drugs's estimated revenue per employee is $100,500
Employee Data
- Rakshit Drugs has 105 Employees.
- Rakshit Drugs grew their employee count by 7% last year.
Rakshit Drugs's People
Name | Title | Email/Phone |
---|
Rakshit Drugs Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $56.6M | 563 | 21% | N/A | N/A |
#2 | $15.6M | 155 | 28% | N/A | N/A |
#3 | $17M | 169 | -11% | N/A | N/A |
#4 | $13.2M | 131 | 8% | N/A | N/A |
#5 | $19.6M | 195 | 10% | N/A | N/A |
#6 | $23.5M | 234 | 7% | N/A | N/A |
#7 | $5.3M | 53 | 0% | N/A | N/A |
#8 | $13M | 129 | -25% | N/A | N/A |
#9 | $20.5M | 204 | 11% | N/A | N/A |
#10 | $11.7M | 116 | 6% | N/A | N/A |
What Is Rakshit Drugs?
Rakshit Drugs Pvt. Ltd. is a pharmaceuticals company based out of Rakshit House,425/3RT, D.No. 7-1-621/328, S.R. Nagar, Hyderabad, India.
keywords:N/AN/A
Total Funding
105
Number of Employees
$10.6M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Rakshit Drugs News
2022-04-20 - Amlodipine Besilate Market Size, Share, Growth 2022-2030| Key ...
VPL Chemicals; Rakshit Drugs; Moehs; Dr. Reddy's; Cadila Pharmaceuticals; Amsal Chem; Changzhou Yabang Pharmaceutical; Cipla; Tapi Teva; Suan.
2022-04-06 - Ukrainian officials begin urging evacuations amid reports of new ...
Sami Rakshit, director of Finnish Customs' Enforcement Department, ... decontamination equipment and drugs that could boost its defenses in...
2022-04-06 - 20,488 ghost companies detected in Hyderabad, 3rd-highest in India
Vizag GST Commissionerate booked a case against Hyderabad-based Rakshit drugs private limited, Virupaksha Organics Limited,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $10.6M | 105 | 25% | N/A |
#2 | N/A | 105 | 7% | N/A |
#3 | N/A | 106 | 25% | N/A |
#4 | $7.7M | 106 | 8% | N/A |
#5 | $17.3M | 107 | 9% | N/A |